A Leading Location
The German capital region provides outstanding potential for development and ideal conditions for the biotechnology and pharmaceuticals industry. Its major strengths are a unique research landscape and a close network of the players along the entire value-added chain. Its many technology parks and networks in various fields of modern biotechnology provide an excellent infrastructure and form the technological backbone of the biotechnology and pharmaceuticals industry in Berlin and Brandenburg.
Are you planning on developing your company’s presence in the German capital? A good choice! We will help you implement your decision to locate or expand your company in Berlin-Brandenburg.
Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project
Myelo Therapeutics GmbH announced today that it was selected as one of four companies worldwide for The Hive, Elsevier's new incubator project for biotech and pharmaceutical start-up firms.
Anti-NMDA receptor encephalitis is an inflammatory disease that affects the central nervous system. It is a rare autoimmune disease that results in the body producing antibodies against the NMDA receptor, a protein that plays an...
Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3) million Series A funding round. Epidarex Capital led the round, and Evotec AG participated...
Enzymes and processes for biomass degradation
Za’abeel Hall, Z2.J50
The Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg is pleased to welcome you to Berlin for the first International GlycoBioTec symposium from 7th – 9th of February 2017.